Pulmonary vascular remodeling in pulmonary hypertension

Cell and Tissue Research

Volumn 367, Issue 3, 2017, Pages 643-649

  Tuder, Rubin M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelial cells; Lung; Pulmonary hypertension; Pulmonary remodeling; Smooth muscle cells

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 20; INTERLEUKIN 6; INTERLEUKIN 8; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVENTITIA; ARTERIAL WALL THICKENING; ARTERY INTIMA PROLIFERATION; DISEASE SEVERITY; HUMAN; INTRACELLULAR SIGNALING; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MACROPHAGE; PATHOGENESIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; T LYMPHOCYTE SUBPOPULATION; VASCULAR REMODELING; ANIMAL; INFLAMMATION; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; VASCULAR REMODELING;

EID: 85007174575     PISSN: 0302766X     EISSN: 14320878     Source Type: Journal    
DOI: 10.1007/s00441-016-2539-y     Document Type: Review

References (45)

1. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121:2747–2754
2. Archer SL, Weir EK, Wilkins MR (2010) Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 121:2045–2066
3. Bjornsson J, Edwards WD (1985) Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 60:16–25
4. Caslin AW, Heath D, Madden B, Yacoub M, Gosney JR, Smith P (1990) The histopathology of 36 cases of plexogenic pulmonary arteriopathy. Histopathology 16:9–19
5. Chazova I, Loyd JE, Newman JH, Belenkov Y, Meyrick B (1995) Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol 146:389–397
6. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM (1999) Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155:411–419
7. Davie NJ, Gerasimovskaya EV, Hofmeister SE, Richman AP, Jones PL, Reeves JT, Stenmark KR (2006) Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularization—a process mediated by hypoxia and endothelin-1. Am J Pathol 168:1793–1807
8. Dorfmuller P, Perros F, Balabanian K, Humbert M (2003) Inflammation in pulmonary arterial hypertension. Eur Respir J 22:358–363
9. Fishman AP (1997) A century of primary pulmonary hypertension. In: Rubin LJ, Rich S (eds) Primary pulmonary hypertension. Lung biology in health and disease. Decker, New York, pp 1–17
10. Graham BB, Bandeira AP, Morrell NW, Butrous G, Tuder RM (2010) Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest 137:20S–29S
11. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX, Humbert M (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54:S10–S19
12. Haworth SG, Rabinovitch M, Meyrick B, Michel R, Pietra GG, Polak JM, Reid LM, Tuder RM (1998) Primary pulmonary hypertension: executive summary from the World Symposium-Primary Pulmonary Hypertension. In: Rich S (ed) World Symposium-Primary Pulmonary Hypertension. World Health Organization, Geneva, pp 2–5
13. Heath D, Edwards JE (1958) The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 18:533–547
14. Heath D, Wagenvoort CA (1975) Classification and nomenclature. In: Hatano S, Strasser T (eds) Primary pulmonary hypertension: report on a WHO meeting, October 15-17, 1973. World Health Organizaiton, Geneva, pp 15–17
15. Hsia CC, Hyde DM, Ochs M, Weibel ER (2010) An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 181:394–418
16. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D (1995) Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151:1628–1631
17. Hyde DM, Harkema JR, Tyler NK, Plopper CG (2006) Design-based sampling and quantitation of the respiratory airways. Toxicol Pathol 34:286–295
18. Kumar R, Mickael C, Chabon J, Gebreab L, Rutebemberwa A, Garcia AR, Koyanagi DE, Sanders L, Gandjeva A, Kearns MT, Barthel L, Janssen WJ, Mauad T, Bandeira A, Schmidt E, Tuder RM, Graham BB (2015) The causal role of IL-4 and IL-13 in Schistosoma mansoni pulmonary hypertension. Am J Respir Crit Care Med 192:998–1008
19. Majka SM, Skokan M, Wheeler L, Harral J, Gladson S, Burnham E, Loyd JE, Stenmark KR, Varella-Garcia M, West J (2008) Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 295:L1028–L1039
20. McMurtry IF, Davidson AB, Reeves JT, Grover RF (1976) Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res 38:99–104
21. Muhlfeld C, Ochs M (2013) Quantitative microscopy of the lung: a problem-based approach. Part 2. Stereological parameters and study designs in various diseases of the respiratory tract. Am J Physiol Lung Cell Mol Physiol 305:L205–L221
22. Newman JH, Holt TN, Hedges LK, Womack B, Memon SS, Willers ED, Wheeler L, Phillips JA 3rd, Hamid R (2011) High-altitude pulmonary hypertension in cattle (Brisket disease): candidate genes and gene expression profiling of peripheral blood mononuclear cells. Pulm Circ 1:462–469
23. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, Fishman AP (1989) Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 80:1207–1221
24. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Detre KM (1989) Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80:1198–1206
25. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM (2004) Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43:25S–32S
26. Pugliese SC, Poth JM, Fini MA, Olschewski A, El Kasmi KC, Stenmark KR (2015) The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. Am J Physiol Lung Cell Mol Physiol 308:L229–L252
27. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT (2012) Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 186:897–908
28. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F (2011) Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 8:443-455
29. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S–12S
30. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna KR, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62:D34–D41
31. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, Walker C, Budd DC, Pepke-Zaba J, Morrell NW (2010) Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122:920–927
32. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM (2012) Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 186:261–272
33. Stenmark KR, Tuder RM, El Kasmi KC (2015) Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension. J Appl Physiol 119:1164–1172
34. Sylvester JT, Shimoda LA, Aaronson PI, Ward JP (2012) Hypoxic pulmonary vasoconstriction. Physiol Rev 92:367–520
35. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon GG, Waltenberger J, Voelkel NF, Tuder RM (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. Faseb J 15:427–438
36. Tuder RM (2014) How do we measure pathology in PAH (lung and RV) and what does it tell us about the disease. Drug Discov Today 19:1257–1263
37. Tuder RM, Erzurum SC (2009) Pulmonary endothelium and pulmonary hypertension. In: Voelkel NF, Rounds S (eds) The pulmonary endothelium: function in health and disease. Wiley-Blackwell, Chichester, pp 449–460
38. Tuder RM, Zaiman AL (2004) Pathology of pulmonary vascular disease. In: Peacock A, Rubin LJ (eds) Pulmonary circulation. Arnold, London, pp 25–32
39. Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275–285
40. Tuder RM, Chacon M, Alger LA, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci MW, Semenza GL, Yacoub M, Polak JM, Voelkel NF (2001) Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 195:367–374
41. Tuder RM, Archer SL, Dorfmuller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW (2013a) Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62:D4–D12
42. Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB (2013b) Pathology of pulmonary hypertension. Clin Chest Med 34:639–650
43. Voelkel NF, Tuder RM, Bridges J, Arend WP (1994) Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 11:664–675
44. Wagenvoort CA, Wagenvoort N (1970) Primary pulmonary hypertension. A pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 42:1163–1184
45. Weibel ER, Gomez DM (1962) Architecture of the human lung. Use of quantitative methods establishes fundamental relations between size and number of lung structures. Science 137:577–585